NYSE : ANVS
Annovis Bio, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.02 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 43.46M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 5.76M | 4.48M | 6.70M | 6.24M | 9.00M | 6.06M |
| Research & Development | 43.77M | 25.22M | 20.00M | 38.79M | 16.52M | 8.48M |
| Operating Expenses | 49.53M | 29.70M | 26.69M | 45.04M | 25.51M | 14.54M |
| Operating Income | -49.53M | -29.70M | -26.69M | -45.04M | -25.51M | -14.54M |
| Interest & Investment Income | 618.09K | 699.06K | 331.85K | 667.90K | 182.71K | 13.34K |
| Other Non Operating Income (Expenses) | -611.34K | 142.00K | 1.77M | -11.84M | 36.75K | |
| Pretax Income | -49.52M | -28.85M | -24.59M | -56.20M | -25.33M | -14.49M |
| Net Income | -49.52M | -28.85M | -24.59M | -56.20M | -25.33M | -14.49M |
| Net Income to Common | -49.52M | -28.85M | -24.59M | -56.20M | -25.33M | -14.49M |
| Shares Outstanding (Basic) | 27.67M | 20.55M | 12.18M | 9.02M | 8.16M | 7.63M |
| Shares Outstanding (Diluted) | 27.67M | 20.55M | 12.24M | 9.02M | 8.16M | 7.63M |
| EPS (Basic) | -1.79 | -1.40 | -2.02 | -6.23 | -3.10 | -1.90 |
| EPS (Diluted) | -1.79 | -1.40 | -2.31 | -6.23 | -3.10 | -1.90 |
| EBIT | -49.53M | -29.70M | -26.69M | -45.04M | -25.51M | -14.54M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 18.73M | 19.53M | 10.55M | 5.75M | 28.38M | 45.69M |
| Cash & Short-Term Investments | 18.73M | 19.53M | 10.55M | 5.75M | 28.38M | 45.69M |
| Prepaid Expenses | 521.37K | 337.07K | 367.41K | 41.53K | 104.89K | 72.85K |
| Other Current Assets | 2.79M | 1.21M | 3.01M | 4.41M | 7.54M | 242.62K |
| Total Current Assets | 22.04M | 21.08M | 13.93M | 10.21M | 36.02M | 46.00M |
| Total Assets | 22.04M | 21.08M | 13.93M | 10.21M | 36.02M | 46.00M |
| Accounts Payable | 3.33M | 2.59M | 2.31M | 1.29M | 3.96M | 688.07K |
| Accrued Expenses | 3.03M | 1.04M | 1.58M | 2.99M | 3.74M | 818.44K |
| Total Current Liabilities | 6.36M | 3.64M | 3.88M | 4.28M | 7.70M | 1.51M |
| Other Long-Term Liabilities | 19.93M | 595.00K | 737.00K | 13.68M | ||
| Total Liabilities | 26.29M | 4.23M | 4.62M | 17.96M | 7.70M | 1.51M |
| Common Stock | 4.26K | 2.72K | 1.41K | 1.05K | 816.00 | 810.00 |
| Additional Paid-In Capital | 191.87M | 180.55M | 144.16M | 102.51M | 82.38M | 73.22M |
| Retained Earnings | -196.13M | -163.70M | -134.85M | -110.26M | -54.05M | -28.73M |
| Total Common Equity | -4.25M | 16.85M | 9.31M | -7.75M | 28.32M | 44.49M |
| Shareholders' Equity | -4.25M | 16.85M | 9.31M | -7.75M | 28.32M | 44.49M |
| Total Liabilities & Equity | 22.04M | 21.08M | 13.93M | 10.21M | 36.02M | 46.00M |
| Net Cash (Debt) | 18.73M | 19.53M | 10.55M | 5.75M | 28.38M | 45.69M |
| Net Cash Per Share | 0.68 | 0.95 | 0.86 | 0.64 | 3.48 | 5.99 |
| Filing Date Shares Outstanding | 42.61M | 28.36M | 19.49M | 11.01M | 8.22M | 8.16M |
| Total Common Shares Outstanding | 42.61M | 27.20M | 14.14M | 10.52M | 8.16M | 8.10M |
| Working Capital | 15.68M | 17.45M | 10.04M | 5.93M | 28.32M | 44.49M |
| Book Value Per Share | -0.10 | 0.62 | 0.66 | -0.74 | 3.47 | 5.49 |
| Tangible Book Value | -4.25M | 16.85M | 9.31M | -7.75M | 28.32M | 44.49M |
| Tangible Book Value Per Share | -0.10 | 0.62 | 0.66 | -0.74 | 3.47 | 5.49 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -49.52M | -28.85M | -24.59M | -56.20M | -25.33M | -14.49M |
| Stock-Based Compensation | 2.59M | 1.80M | 3.84M | 4.63M | 9.15M | 4.70M |
| Other Operating Activities | -978.00K | -142.00K | -1.82M | 11.84M | ||
| Change in Accounts Payable | 2.35M | 284.54K | 1.01M | -2.67M | 3.27M | 346.22K |
| Change in Other Net Operating Assets | 2.22M | 1.29M | -331.43K | 2.44M | -4.41M | 311.13K |
| Operating Cash Flow | -43.34M | -25.62M | -21.89M | -39.97M | -17.31M | -9.13M |
| Issuance of Common Stock | 44.94M | 34.60M | 26.69M | 17.34M | 4.61K | 46.74M |
| Financing Cash Flow | 44.94M | 34.60M | 26.69M | 17.34M | 4.61K | 46.74M |
| Net Cash Flow | 1.60M | 8.98M | 4.80M | -22.62M | -17.31M | 37.61M |
| Levered Free Cash Flow | -23.79M | -15.18M | -12.17M | -23.75M | -7.93M | -3.73M |
| Unlevered Free Cash Flow | -23.79M | -15.18M | -12.17M | -23.75M | -7.93M | -3.73M |
| Change in Working Capital | 4.57M | 1.58M | 681.71K | -228.60K | -1.14M | 657.35K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 45.59M | 91.70M | 69.40M | 191.90M | 109.64M | 142.41M |
| Enterprise Value | 26.86M | 76.41M | 56.76M | 185.55M | 77.65M | 94.95M |
| Last Close Price | 1.13 | 3.46 | 5.03 | 18.70 | 13.43 | 17.58 |
| PB Ratio | 5.44 | 7.46 | -24.76 | 3.87 | 3.20 | |
| P/TBV Ratio | 5.44 | 7.46 | 3.87 | 3.20 | ||
| Net Debt / Equity Ratio | 4.40 | -1.16 | -1.13 | 0.74 | -1.00 | -1.03 |
| Quick Ratio | 2.94 | 5.37 | 2.72 | 1.34 | 3.69 | 30.33 |
| Current Ratio | 3.47 | 5.80 | 3.59 | 2.39 | 4.68 | 30.54 |
| Return on Equity (ROE) | -703.68% | -220.61% | -3,159.09% | -546.40% | -69.57% | -55.68% |
| Return on Assets (ROA) | -142.36% | -106.03% | -138.26% | -121.77% | -38.88% | -33.58% |
| Return on Capital Employed (ROCE) | -315.90% | -170.20% | -265.80% | -759.60% | -90.10% | -32.70% |
| Earnings Yield | -167.24% | -31.47% | -35.43% | -29.29% | -23.10% | -10.17% |
| Buyback Yield / Dilution | -73.71% | -67.97% | -35.60% | -10.55% | -7.03% | -20.88% |